Description: Pancreatic cancer and normal tissue array, including pathology grade, TNM/Stage ( AJCC 7th edition), 80 cases/80 cores (core size 1.5mm), replacing PA804a

Description: Phosphodiesterases (PDEs) play an important role in the dynamic regulation of cAMP and cGMP signaling. PDE4B has 3',5'-cyclic-AMP phosphodiesterase activity and degrades cAMP. Inhibition of PDE4B activity by its inhibitors leads to an elevated intracellular level of cAMP. The PDE4B gene encodes at least 4 different isoforms, and has been linked to inflammation in monocytes by its regulation of the toll-receptor pathway. It is also highly expressed in the central nervous system, and has been targeted as a potential treatment for autism, depression, schizophrenia, and other conditions._x000D_The PDE4B cell-based activity assay kit is designed for screening inhibitors of PDE4B1 in cultured cells. The assay is based on transfecting cells with the CRE luciferase reporter. CRE reporter contains the firefly luciferase gene under the control of cAMP response element (CRE). Elevation of intracellular cAMP activates CRE binding protein (CREB) to bind CRE and induce the expression of luciferase. Forskolin is commonly used to raise the intracellular level of cAMP in cell physiology studies. When cells transiently transfected with CRE reporter are activated by forskolin, the intracellular level of cAMP is upregulated, which induces the expression of CRE luciferase reporter. However, when cells are co-transfected with PDE4B1 expression vector and CRE reporter, the level of forskolin-induced cAMP is reduced, resulting in lower expression level of luciferase. When cells are treated with PDE4B inhibitor to inhibit PDE4B1 activity, cAMP level is restored, resulting in higher luciferase activity._x000D_The kit includes CRE luciferase reporter (premixed with constitutively-expressing Renilla (sea pansy) luciferase vector that serves as an internal control for transfection efficiency), PDE4B1 expression vector, and forskolin.

Description: The PDE4D cell-based activity assay is designed for screening inhibitors of PDE4D7 in cultured cells. The assay is based on transfecting cells with the CRE luciferase reporter. _x000D_CRE reporter contains the firefly luciferase gene under the control of cAMP response element (CRE). Elevation of intracellular cAMP activates CRE binding protein (CREB) to bind CRE and induce the expression of luciferase. When cells transiently transfected with CRE reporter are activated by forskolin, the intracellular level of cAMP is upregulated, which induces the expression of CRE luciferase reporter. However, when cells are co-transfected with PDE4D7 expression vector and CRE reporter, the level of forskolin-induced cAMP is reduced, resulting in lower expression level of luciferase. When cells are treated with PDE4D inhibitor to inhibit PDE4D7 activity, cAMP level is restored, resulting in higher luciferase activity.

Description: This liquid Assay Medium is optimized for use with the PD-1 cell-based assay using the BPS Bioscience's PD-1/NFAT Reporter-Jurkat cell line (Cat #60535). _x000D_

Description: The human IDO1 Cell-Based Assay Kit is designed to monitor the activity of exogenously expressed human IDO1 in cultured cells.

Description: Pancreatic cancer with pancreas tissue array, including ductal adenocarcinoma(PADC),acinar cell carcinoma(PACC),normal adjacent and pancreas tissue,pathology grade, TNM and clinical stage, 96 cases/192 cores(1.0mm), replacing PA2082

Description: Pancreatic cancer with pancreas tissue array, including duct adenocarcinoma(PDAC), acinar cell carcinoma(PACC),squamous cell carcinoma,normal adjacent pancreas and normal tissuepathology grade, TNM and clinical stage, 80 cases/80 cores(1.5mm), replacing PA805b

Description: Pancreatic cancer with pancreas tissue array, including pathology grade, TNM and clinical stage, 6 cases/24 cores, replacing T141b

Description: Pancreatic cancer tissue array with cancer adjacent tissue, including pathology grade, TNM and clinical stage, 12 cases/24 cores, replacing PA242d

Description: Included Diagnoses: Adenocarcinoma (including all subtypes) and Squamous Cell Carcinoma (including all subtypes), Neuroendocrine tumors of the Pancreas, Carcinoma of the Pancreas.